Literature DB >> 16709516

Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature.

Nabil M Nuamah1, Hakan Goker, Yusuf A Kilic, Hassen Dagmoura, Atilla Cakmak.   

Abstract

Human granulocyte colony-stimulating factor (G-CSF) is a hematopoietic hormone promoting the growth, proliferation, differentiation and maturation of myeloid and leukocytic lineages. G-csfs have been used to improve granulocyte count in neutropenic patients, reduce the incidence and duration of neutropenia in patients receiving cytotoxic chemotherapy and to mobilize peripheral blood stem cells prior to leukapheresis for using in both autologous and allogeneic hematopoietic cell transplantation. In general, side-effects are mild to moderate and life threatening side-effects like splenic rupture are very rare. We herein, report a case of spontaneous splenic rupture secondary to high-dose G-CSF use (20 mcg/kg/day), in a healthy female allogeneic donor of peripheral-blood stem cell (PBSC) .

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709516

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  18 in total

Review 1.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

2.  [Rupture of the spleen. Clinicopathological correlations and diagnostic procedures].

Authors:  A Tzankov; H Adams; W Sterlacci
Journal:  Pathologe       Date:  2008-03       Impact factor: 1.011

Review 3.  G-CSF in Healthy Allogeneic Stem Cell Donors.

Authors:  Kristina Hölig
Journal:  Transfus Med Hemother       Date:  2013-07-22       Impact factor: 3.747

4.  Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.

Authors:  Ruth Pettengell; Peter Bias; Udo Mueller; Nicole Lang
Journal:  Support Care Cancer       Date:  2016-01-16       Impact factor: 3.603

5.  Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee.

Authors:  R N Lown; J Philippe; W Navarro; S M van Walraven; L Philips-Johnson; M Fechter; R Pawson; M Bengtsson; M Beksac; S Field; H Yang; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

Review 6.  Hematopoietic stem cell donation.

Authors:  Shu-Huey Chen; Tso-Fu Wang; Kuo-Liang Yang
Journal:  Int J Hematol       Date:  2013-02-19       Impact factor: 2.490

7.  Severe events in donors after allogeneic hematopoietic stem cell donation.

Authors:  Joerg Halter; Yoshihisa Kodera; Alvaro Urbano Ispizua; Hildegard T Greinix; Norbert Schmitz; Geneviève Favre; Helen Baldomero; Dietger Niederwieser; Jane F Apperley; Alois Gratwohl
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

Review 8.  Concise review: next-generation cell therapies to prevent infections in neutropenic patients.

Authors:  Marion E G Brunck; Lars K Nielsen
Journal:  Stem Cells Transl Med       Date:  2014-03-05       Impact factor: 6.940

Review 9.  Stem cell donation--what advice can be given to the donor?

Authors:  Derwood Pamphilon; Samreen Siddiq; Susan Brunskill; Carolyn Dorée; Chris Hyde; Mary Horowitz; Simon Stanworth
Journal:  Br J Haematol       Date:  2009-08-13       Impact factor: 6.998

Review 10.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.